Quality support

Our Global Regulatory Affairs and CMC Consulting Services

Clients benefit from our team’s extensive experience with Health Canada, the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA) to streamline global regulatory pathways. Regulatory approval is achieved through a clear strategy and an execution focused plan. We provide strategic assessments and practical guidance for global markets, building scalable project models tailored to specific needs and budgets.
Our team delivers integrated solutions for international regulatory requirements, clarifying pathways and managing submissions for pharmaceuticals, biologics, and medical devices across North America and Europe. Our strategies are based on direct regulatory experience and agency knowledge, providing sponsors with clear guidance on development, Chemistry, Manufacturing, and Controls (CMC), and clinical requirements.
From initial due diligence to post approval lifecycle management, our CMC Regulatory Compliance specialists prepare, review, and file submissions with precision. We emphasize proactive problem solving to help clients achieve and maintain compliance at every stage of the product lifecycle in all major jurisdictions.

GxP Cellators regulatory affairs and agency liaison
Agencies we work with Global & Regional Authorities
  • Health Canada
  • US FDA
  • EMA
  • MHRA
  • TGA
  • WHO
  • PMDA
  • ICH Q10
  • ICH GCP E6(R3)
  • 21 CFR Part 58
  • 21 CFR Part 11
  • GAMP 5
  • ALCOA+
  • OECD
  • EU GDP
  • WHO GDP
  • DSCSA
  • FMD

Applicable Standards and Regulations:

What we do

Our Global Regulatory and CMC Support Services

01 / 07

Strategic Regulatory Planning and Agency Interactions

Successful market access starts with a well defined regulatory strategy. We work with clients to identify the most efficient and low risk pathway to approval, tailored to each product’s unique characteristics and business objectives.

    • Special Regulatory Designations

      We identify and pursue opportunities for expedited development and review to accelerate product timelines.

      • Orphan Drug Designation (ODD): Preparation and submission of ODD applications to both the FDA and EMA, articulating medical plausibility and prevalence criteria to secure development incentives and market exclusivity.
      • Pediatric Study Planning: Strategic guidance for developing and negotiating Pediatric Investigation Plans (PIPs) for EMA and Pediatric Study Plans (PSPs) for FDA, ensuring compliance with pediatric regulatory requirements.
      • Breakthrough and PRIME Designation: Assistance with requests for FDA Breakthrough Therapy Designation or EMA PRIME scheme, highlighting the product's potential to address unmet medical needs.
      • FDA Fast Track and Priority Review: Strategic assessment and preparation of requests for Fast Track designation and Priority Review eligibility.
      Applicable Standards: FDA Guidance for Industry (ODD, Fast Track, Priority Review), EMA Guidelines on Orphan Medicinal Products, Paediatric Regulation (EC) No 1901/2006, ICH E11 (pediatric populations).
    • Regulatory Intelligence and Horizon Scanning

      We continuously monitor the evolving regulatory landscape, providing proactive updates on new guidelines, emerging expectations, and policy changes that may impact product portfolios across FDA, EMA, and Health Canada.

      Applicable Standards: All applicable ICH, FDA, EMA, Health Canada, MHRA, TGA, WHO, and PIC/S guidance documents.
    • Pre-Submission Meeting Preparation

      Engaging with health authorities before submission is essential. We prepare, author, and strategically plan for meetings with global agencies, including:

      • Health Canada Type C and Pre-Submission meetings, including preparation of meeting request packages, briefing documents, and presentation materials.
      • FDA Type A, B, and C meetings (Pre-IND, End-of-Phase 2, Pre-NDA/BLA). We craft the meeting request, develop the briefing book, and provide coaching for productive discussions.
      • EMA Scientific Advice and Protocol Assistance meetings. We manage the entire process, from drafting the briefing document to coordinating with national authorities and facilitating follow-up responses.
      Applicable Standards: FDA Guidance on Formal Meetings, Health Canada Management of Drug Submissions and Applications, EMA Scientific Advice Guidelines, ICH E6 (GCP).
    • Global Regulatory Strategy Development

      Comprehensive regulatory roadmaps identify optimal submission pathways, target markets, and timelines. These strategies cover the entire product lifecycle, from early development through commercialization and beyond.

      Applicable Standards: ICH M4 (Common Technical Document), regional submission requirements from Health Canada, FDA, EMA, MHRA, and TGA.

02 / 07

Clinical Trial Applications (CTA) & Investigational Product Submissions

Initiating clinical trials requires meticulous preparation and submission of comprehensive applications that satisfy the unique requirements of each jurisdiction.

    • Health Canada CTA

      End-to-end consulting is provided for Clinical Trial Applications (CTA) submissions, including preparation of the application kit, protocol assessment, Investigator’s Brochure review, and ongoing CTA amendments and renewals.

    • EMA CTA & CTIS Submissions

      Coordination and preparation of Clinical Trial Applications in accordance with the EU Clinical Trials Regulation (EU CTR 536/2014) and submission via the Clinical Trials Information System (CTIS) are provided. Part I and Part II documentation, timelines, and sponsor interactions are managed by the team.

    • Clinical Trial Application Maintenance

      Ongoing support for CTA amendments, protocol deviations reporting, annual progress reports, and end-of-trial notifications across all three jurisdictions.

    • FDA IND

      Comprehensive preparation and management of Investigational New Drug (IND) submissions to the US FDA are provided. This includes authoring the IND in eCTD format, managing annual reports, and preparing responses to FDA clinical holds or information requests.

    • Medical Device ITA & IDE

      • Health Canada Guidance and preparation are provided for Investigational Testing Authorization (ITA) applications for significant risk medical device trials.
      • FDA Preparation and submission of Investigational Device Exemption (IDE) applications for clinical studies, including both feasibility and pivotal trials, are conducted with expertise in FDA IDE regulations (21 CFR Part 812).

Applicable Standards: ICH E6 (GCP), EU CTR 536/2014, FDA 21 CFR Part 312 (IND), FDA 21 CFR Part 812 (IDE), Health Canada Clinical Trial Regulations, ISO 14155 (clinical investigation of medical devices), ICH E2A (clinical safety data management).

03 / 07

CMC Due Diligence, Strategy and Compliance

The Chemistry, Manufacturing, and Controls (CMC) section is often the most scrutinized part of any regulatory submission. Our CMC Regulatory Compliance specialists provide deep scientific and regulatory expertise to ensure that quality packages are robust, coherent, and submission ready.

    • CMC Due Diligence & Gap Analysis

      Thorough assessment of existing CMC packages against Health Canada, FDA, and EMA expectations is conducted to identify risks, gaps, and opportunities for optimization prior to submission. Analytical methods, manufacturing processes, specifications, and stability data are evaluated to ensure alignment with ICH guidelines and regional expectations.

    • Investigational Medicinal Product Dossier (IMPD)

      Authoring of IMPDs for European clinical trial applications is conducted, ensuring alignment with the quality requirements of the EU CTR and preparedness for potential inspections.

    • Response Management

      Rapid and effective preparation of responses to Health Authority questions and deficiency letters. Our specialists craft scientifically sound, clearly justified arguments to facilitate the swift resolution of queries and to move your application forward.

    • Supplier & CMO Qualification Support

      Assistance is provided with the selection, technical assessment, and qualification of third-party manufacturers and suppliers. Gap analyses are conducted, and remediation support is offered to ensure CMOs meet global GMP and regulatory expectations.

    • Pharmaceutical Development Planning

      Strategic guidance is provided on Quality by Design (QbD) initiatives, identification of Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs), and development of control strategies that support robust manufacturing and regulatory flexibility.

    • Regulatory CMC Dossier Preparation & Review

      Expert authoring, compilation, and critical review of quality modules are provided across the Common Technical Document (CTD) format.

      • Module 3 (Quality): Comprehensive authoring of drug substance and drug product sections for small molecules, biologics (including cell and gene therapies), biosimilars, and natural health products.
      • Master Files: Preparation and maintenance of Drug Master Files (DMFs) for FDA (Type II, III, IV), Active Substance Master Files (ASMFs) for Europe, and equivalent filings for Health Canada are provided.
      • BLA/NDA/ANDS Readiness: The CMC section of marketing applications is ensured to be complete, consistent, and compliant with regional eCTD specifications and agency-specific expectations.

Applicable Standards: ICH Q1A/E (stability), Q2 (analytical validation), Q3 (impurities), Q6 (specifications), Q7 (API), Q8 (pharmaceutical development), Q9 (quality risk management), Q10 (pharmaceutical quality system), M4 (CTD), FDA 21 CFR Part 211, EU GMP Annex 11 (computerised systems), EU GMP Annex 15 (qualification and validation), Health Canada GMP guidelines (C.02.015 to C.02.029), PIC/S GMP Guide, ISPE Baseline Guides, ASTM E2500 (commissioning and qualification).

04 / 07

Post-Approval CMC and Lifecycle Management

Maintaining compliance after approval requires vigilant management of changes and ongoing regulatory obligations. We provide strategic and operational support to ensure that products remain compliant throughout their lifecycle.

    • Post-Approval Change Management

      Strategic assessment and execution of post-approval changes are provided, including manufacturing site transfers, process improvements, specification updates, and container closure system changes.

      • FDA Preparation and submission of Prior Approval Supplements (PAS), Changes Being Effected (CBE-30 and CBE-0), and Annual Reportable changes.
      • EMA Management of Type IA, Type IB, and Type II Variation submissions, including coordination across affected member states where applicable.
      • Health Canada Preparation and submission of Post-DIN Changes (Quality, Safety, and Efficacy submissions), including Notifiable Changes (NCs) and Supplement to a DIN Submission (SDS).
    • Commitment Tracking & Management

      Systematic tracking and execution of post-marketing commitments and requirements are provided, ensuring timely fulfillment and regulatory reporting to avoid compliance issues.

    • Lifecycle Maintenance Submissions

      Preparation and submission of annual reports, renewals, and other periodic updates are provided.

      • FDA Annual Reports: For NDAs, BLAs, and ANDAs, summarizing changes, new data, and stability commitments.
      • EMA Renewals: Management of the marketing authorization renewal process, including preparation of renewal applications and coordination with reference member states.
      • Health Canada Annual Reviews: Integration with Product Quality Reviews (PQRs) and annual compliance reporting.
    • Stability Program Oversight

      Design and management of stability studies are provided to support shelf-life extensions, post-approval changes, and ongoing commitment batches. Oversight of protocol development, data review, and statistical analysis is conducted to ensure compliance with ICH Q1A/E requirements.

Applicable Standards: ICH Q1A/E (stability), Q10 (pharmaceutical quality system), FDA 21 CFR Part 314 (NDA/ANDA), EU Variations Regulation (EC) No 1234/2008, Health Canada Post-DIN Changes Guidance, PIC/S GMP Guide.

05 / 07

Product Registration and Market Access

Achieving marketing authorization is the gateway to commercial success. We provide guidance through complex registration processes for pharmaceuticals, biologics, and medical devices.

    • Pharmaceuticals & Biologics Registration

      • FDA New Drug Applications (NDA), Biologics License Applications (BLA), and Abbreviated New Drug Applications (ANDA). We provide end-to-end support, from pre-submission meetings to final approval.
      • EMA Marketing Authorization Applications (MAA) via Centralized, Decentralized (DCP), or Mutual Recognition (MRP) Procedures. We provide guidance on procedure selection, rapporteur choice, and the entire assessment process.
      • Health Canada New Drug Submissions (NDS), Abbreviated New Drug Submissions (ANDS), and Supplemental Submissions (SNDS). Our team possesses deep expertise in Health Canada's submission requirements and review processes.
      • Natural Health Products (NHPs): Preparation and submission of NHP Product License Applications, including evidence summaries, quality documentation, and label reviews in compliance with the Natural Health Products Regulations.
    • Labelling & Artwork Development

      Pre-approval and post-approval label reviews to ensure compliance with regional requirements for product cartons, inserts, package inserts, and Product Monographs. We support you in maximizing claims while maintaining regulatory alignment.

    • Medical Device Registration

      • FDA 510(k) Pre-market Notification, De Novo requests, and Premarket Approval (PMA) applications. We assist with device classification, substantial equivalence arguments, and clinical data summaries.
      • Health Canada Registration of Class I to IV medical devices, including Medical Device Licence (MDL) applications for Class II to IV devices and Medical Device Establishment Licence (MDEL) applications for Class I importers and distributors.
      • EU MDR/IVDR: Preparation of Technical Documentation for CE Marking under the Medical Device Regulation (MDR 2017/745) and In Vitro Diagnostic Regulation (IVDR 2017/746). We assist with classification, selecting the conformity assessment route, and interacting with Notified Bodies.
    • OTC & Cosmetics

      Regulatory classification, monograph compliance assessments, and label reviews for over-the-counter drug products and cosmetics, including Drug Identification Number (DIN) applications and cosmetic notifications.

Applicable Standards: ICH M4 (CTD), FDA 21 CFR Parts 314 (NDA), 601 (BLA), 814 (PMA), 807 (510(k)), EU MDR 2017/745, IVDR 2017/746, Health Canada Medical Devices Regulations, Natural Health Products Regulations, Food and Drug Regulations, ISO 13485 (medical devices), ISO 9001 (quality management).

06/ 07

Pharmacovigilance and Post-Market Surveillance

Ensuring patient safety and compliance with pharmacovigilance (PV) obligations is critical throughout the product lifecycle.

    • PV System Establishment

      Design and implementation of pharmacovigilance systems are provided to meet global requirements, including appointment of an EU Qualified Person for Pharmacovigilance (QPPV) and a US FDA Pharmacovigilance Responsible Person.

    • Adverse Event Management

      Procedures are established for adverse event collection, processing, evaluation, and expedited reporting to health authorities (e.g., FDA MedWatch, Health Canada Vigilance, Surveillance).

    • Signal Detection & Management

      Signal detection activities are implemented, including literature scanning, data mining, and trend analysis, to identify and evaluate emerging safety signals.

    • Pharmacovigilance System Master File (PSMF)

      Authoring and maintenance of the PSMF for EU compliance, ensuring it accurately reflects the PV system and is inspection ready.

    • Risk Management Plans (RMP)

      Development of EU RMPs and FDA Risk Evaluation and Mitigation Strategies (REMS), including safety specification, pharmacovigilance plan, and risk minimization measures.

    • Periodic Reports

      Preparation of Periodic Safety Update Reports (PSURs), Periodic Benefit-Risk Evaluation Reports (PBRERs), and Annual Summary Reports (ASRs) is provided in compliance with ICH E2C(R2) and regional requirements.

Applicable Standards: EU GVP Modules I through XVI, ICH E2A, E2B, E2C, E2D, E2E (pharmacovigilance), FDA 21 CFR Part 312 and 314 (IND and NDA safety reporting), Health Canada Pharmacovigilance requirements, WHO pharmacovigilance guidelines, ISO 9001 (quality management).

07 / 07

Quality Systems and Compliance

Robust quality systems underpin regulatory success. We provide comprehensive support to establish, maintain, and continuously improve quality and compliance posture.

    • Quality Management System (QMS) Design

      Development and implementation of GMP, GLP, GCP, GDP, GVP, and GACP compliant quality systems, including policies, procedures, and work instructions tailored to your organizational structure.

    • Deviation, CAPA, and Change Control

      Design and optimization of quality processes for deviation management, root cause analysis, CAPA implementation, and change control to ensure effective issue resolution and continuous improvement.

    • Product Quality Review (PQR)

      Preparation and review of annual Product Quality Reviews (PQRs/APQRs), including analysis of quality trends and identification of opportunities for process and product improvement.

    • Inspection Readiness and Hosting

      Comprehensive preparation for health authority inspections, including mock inspections, staff training, and document organization. We provide real-time support during FDA, Health Canada, and EMA inspections, including scribe services and response management.

    • Audit Support

      Third-party audit services for suppliers, CMOs, and internal operations. We conduct gap analyses and provide remediation guidance to ensure compliance with global GMP, GLP, and GDP standards.

    • Recall Management

      Development of recall procedures and management of product recall activities, including health hazard evaluations, recall strategy, and communication with health authorities and customers.

Applicable Standards: ICH Q9 (quality risk management), Q10 (pharmaceutical quality system), FDA 21 CFR Parts 210 and 211 (GMP), EU GMP Annex 1 (sterile products), Annex 11 (computerised systems), Annex 15 (qualification and validation), Health Canada GMP guidelines, PIC/S GMP Guide, ISO 9001, ISO 13485, ISO 14644, ISO 17025, ISO 14698, WHO GACP guidelines, EU GACP guidelines (EMEA/HMPC/246816/2005), Health Canada Cannabis Regulations.

Contact

Reach Out to Us

For more details or to discuss your project requirements, please reach out to us. Your query will be handled with complete confidentiality and we will ensure a prompt response.

Our Presence
Saskatchewan, Canada
Calgary, Canada
Toronto, Canada
North Carolina, USA
Frankfurt, Germany
Indiana, USA

    You cannot copy content of this page

    Verified by MonsterInsights